Fig. 3: Combination treatment with CCR2 antagonist RS504393 and anti-PD-1 controls lung metastatic nodules.
From: Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
a Visual quantification by ×10 magnification of metastatic B16F10 lung nodules at euthanasia on day 14 post tumor cell injection. Each dot represents a biologically independent mouse. Mean ± SD. Statistical significance determined by one-way ANOVA. b Lung weight of mice bearing B16F10 lung metastases. Each dot represents a biologically independent mouse. Mean ± SD. Statistical significance determined by one-way ANOVA. c Representative images of murine pulmonary lung metastases at 28 days following intravenous (tail vein) inoculation of B16F10. Flow cytometric analysis of lung infiltrating (d) alveolar macrophages and (e) immune cell subsets. Box plot with min/max whiskers. n = 5 biologically independent mice per group. Statistical significance determined by two-way ANOVA. If statistical significance not indicated in the figure, p > 0.05. Alveolar macrophage (AM), monocyte (Mono), interstitial macrophage (IM), interstitial macrophage subtype 1 (IM1), interstitial macrophage subtype 2 (IM2), interstitial macrophage subtype 3 (IM3), and dendritic cell (DC).
